Mylan Loses Bid to End States’ Generic Drug Price-Fixing Claims

Mylan Pharmaceuticals Inc. will have to face antitrust claims that it conspired with other drugmakers to inflate generic drug prices after a federal judge found sufficient evidence that the company participated in the conspiracy.

Judge Michael P. Shea of the US District Court for the District of Connecticut on Jan. 9 denied Mylan’s motion for summary judgment, saying that testimony from witnesses and phone calls between the drugmaker and competitors suggested the company was involved.

“This evidence is enough to permit a reasonable juror, drawing all inference in favor of the States, to find that Mylan joined the overarching conspiracy,” ...